Leonid Timashev
Stock Analyst at RBC Capital
(4.82)
# 489
Out of 5,125 analysts
574
Total ratings
52.8%
Success rate
16.4%
Average return
Main Sectors:
Stocks Rated by Leonid Timashev
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LEGN Legend Biotech | Maintained: Buy | $56 → $50 | $20.41 | +144.98% | 50 | Nov 11, 2026 | |
| CRMD CorMedix | Reiterated: Buy | $14 → $15 | $5.37 | +179.33% | 18 | Nov 10, 2026 | |
| ADCT ADC Therapeutics | Reiterated: Hold | $2 | $1.51 | +32.45% | 21 | Nov 9, 2026 | |
| CATX Perspective Therapeutics | Reiterated: Hold | $4 | $0.7864 | +408.65% | 13 | Nov 9, 2026 | |
| CMPS COMPASS Pathways | Reiterated: Buy | $21 | $9.25 | +127.03% | 20 | Nov 9, 2026 | |
| EXEL Exelixis | Reiterated: Hold | $58 | $70.58 | -17.82% | 20 | Nov 9, 2026 | |
| PRAX Praxis Precision Medicines | Reiterated: Buy | $462 → $478 | $337.59 | +41.59% | 4 | Nov 9, 2026 | |
| XNCR Xencor | Reiterated: Buy | $43 | $39.39 | +9.16% | 12 | Nov 9, 2026 | |
| CGON CG Oncology | Reiterated: Buy | $79 → $80 | $72.64 | +10.13% | 12 | Nov 6, 2026 | |
| PYXS Pyxis Oncology | Rated: Buy | $6 → $7 | $1.63 | +329.45% | 21 | Nov 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $19 → $18 | $8.73 | +106.19% | 20 | Nov 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $20 → $19 | $10.65 | +78.40% | 26 | Nov 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $59 | $46.53 | +26.80% | 45 | Nov 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $20 → $17 | $4.20 | +304.76% | 16 | Nov 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $459 → $465 | $424.00 | +9.67% | 21 | Nov 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $260 → $321 | $193.06 | +66.27% | 19 | Nov 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $113 | $56.18 | +101.14% | 29 | Nov 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $42 | $19.18 | +118.98% | 29 | Nov 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $56 → $57 | $46.47 | +22.66% | 25 | Nov 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $48 → $45 | $31.75 | +41.73% | 15 | Nov 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $296 → $305 | $245.43 | +24.27% | 17 | Nov 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $295 → $273 | $140.97 | +93.66% | 44 | Nov 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $5 | $3.69 | +35.50% | 6 | Oct 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $195 | $119.49 | +63.19% | 28 | Oct 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $22 | $15.11 | +45.60% | 35 | Oct 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $287 | $280.78 | +2.22% | 1 | Sep 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $120 → $90 | $14.75 | +510.17% | 7 | May 14, 2026 |
Legend Biotech
Nov 11, 2026
Maintained: Buy
Price Target: $56 → $50
Current: $20.41
Upside: +144.98%
CorMedix
Nov 10, 2026
Reiterated: Buy
Price Target: $14 → $15
Current: $5.37
Upside: +179.33%
ADC Therapeutics
Nov 9, 2026
Reiterated: Hold
Price Target: $2
Current: $1.51
Upside: +32.45%
Perspective Therapeutics
Nov 9, 2026
Reiterated: Hold
Price Target: $4
Current: $0.7864
Upside: +408.65%
COMPASS Pathways
Nov 9, 2026
Reiterated: Buy
Price Target: $21
Current: $9.25
Upside: +127.03%
Exelixis
Nov 9, 2026
Reiterated: Hold
Price Target: $58
Current: $70.58
Upside: -17.82%
Praxis Precision Medicines
Nov 9, 2026
Reiterated: Buy
Price Target: $462 → $478
Current: $337.59
Upside: +41.59%
Xencor
Nov 9, 2026
Reiterated: Buy
Price Target: $43
Current: $39.39
Upside: +9.16%
CG Oncology
Nov 6, 2026
Reiterated: Buy
Price Target: $79 → $80
Current: $72.64
Upside: +10.13%
Pyxis Oncology
Nov 6, 2026
Rated: Buy
Price Target: $6 → $7
Current: $1.63
Upside: +329.45%
Nov 6, 2026
Rated: Buy
Price Target: $19 → $18
Current: $8.73
Upside: +106.19%
Nov 5, 2026
Reiterated: Buy
Price Target: $20 → $19
Current: $10.65
Upside: +78.40%
Nov 5, 2026
Reiterated: Buy
Price Target: $59
Current: $46.53
Upside: +26.80%
Nov 5, 2026
Rated: Buy
Price Target: $20 → $17
Current: $4.20
Upside: +304.76%
Nov 5, 2026
Rated: Buy
Price Target: $459 → $465
Current: $424.00
Upside: +9.67%
Nov 5, 2026
Rated: Buy
Price Target: $260 → $321
Current: $193.06
Upside: +66.27%
Nov 4, 2026
Reiterated: Buy
Price Target: $113
Current: $56.18
Upside: +101.14%
Nov 4, 2026
Rated: Buy
Price Target: $42
Current: $19.18
Upside: +118.98%
Nov 3, 2026
Rated: Buy
Price Target: $56 → $57
Current: $46.47
Upside: +22.66%
Nov 3, 2026
Rated: Buy
Price Target: $48 → $45
Current: $31.75
Upside: +41.73%
Nov 3, 2026
Reiterated: Buy
Price Target: $296 → $305
Current: $245.43
Upside: +24.27%
Nov 2, 2026
Rated: Buy
Price Target: $295 → $273
Current: $140.97
Upside: +93.66%
Oct 29, 2026
Reiterated: Hold
Price Target: $5
Current: $3.69
Upside: +35.50%
Oct 29, 2026
Rated: Buy
Price Target: $195
Current: $119.49
Upside: +63.19%
Oct 27, 2026
Reiterated: Hold
Price Target: $22
Current: $15.11
Upside: +45.60%
Sep 9, 2026
Reiterated: Buy
Price Target: $287
Current: $280.78
Upside: +2.22%
May 14, 2026
Reiterated: Hold
Price Target: $120 → $90
Current: $14.75
Upside: +510.17%